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Inhibition of HSV-1 DNA synthesis with either ~abinosyladenine plus the adenosine 
deaminase inhibitor pentostatin, or with arabinosylthymine, showed a viral mRNA popula- 
tion identical to that seen prior to viral DNA replication (early) by the criteria of quantitative 
hybridization, specific mRNA species identifiable by Southern blot hybridization of size- 
~aetionated RNA, and migration of polypeptides resolved by in vitro translation of purified 
viral mRNA. The amount of viral mRNA associated with infected cell polyribosomes was 
determined by quantitative DNA excess solution hybridization. At 2 hr postinfection (p.i.) 
(before viral DNA synthesis) and in drug-treated cells at 6 hr p.i., the majority of the 
polyadenylated RNA was cell specific with some virus-specific RNA detectable. In contrast, 
at 6 hr p.i., in the absence of drugs (during m~imum viral DNA synthesis), nearly all the 
polyadenylated polyribosomal RNA was viral. Blot hybridization of size-fractionated viral 
RNA confirmed several specific differences between the viral mRNA species occurring 
before and after HSV-1 DNA synthesis, which have been reported previously from this 
laboratory. These differences also were reflected in the in &ro translation products encoded 
by the viral mRNAs. The mRNA species and the eneoded polypeptides that were present 
in the absence of viral DNA synthesis are a subset of those viral mRNA species and poly- 
peptides expressed in the presence of viral DNA synthesis. The viral mRNA species fall 
into several groups based on their relative abundance at various times of infection. These 
data suggest that, in the normal virus infection cycle, the onset of viral DNA synthesis 
is necessary for normal expression of later viral genes. 
INTRODUCTION 
Much information is accumulating on the 
transcriptional and translational events in 
herpes simplex virus type 1 (HSV-1) in- 
fected cells. However, the role of HSV-1 
DNA replication in the temporal control of 
viral mRNA expression is not well under- 
stood. Although viral mRNA sequences ex- 
pressed after viral DNA replication (late) 
are also detectable before replication (early) 
(Kozak and Roizman, 1974; Roizman et al., 
1974), it is very clear that differences in 
abundance of viral mRNAs exist (Silverstein 
et al., 1973; Swanstrom and Wager, 1974; 
Swanstrom et al., 1975; Stringer et al., 
19’77). Prior to viral DNA replication, viral 
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mRNA species representing approximately 
25% of the HSV-1 DNA sequences are found 
in lo- to ZO-fold higher concentrations than 
the mRNA species representing an addi- 
tional 20% of the viral genome. By 6 hr 
postinfection (p.i.>, when viral DNA synthe- 
sis is maximal, 40 to 45% of the viral genome 
is represented as abundant RNA. However, 
inhibitors of DNA synthesis prevent this 
change in abundance class ratio (Swanstrom 
et at., 1975). 
Approximately 50 virus-specific polypep- 
tides have been identified in HSV-1 infected 
cells (Honess and Roizman, 1973; Marsden 
et al., 1976). These have been differentiated 
into three groups -CY, p, and y-based on 
their kinetics of synthesis (Honess and Roiz- 
man, 1974). The a! polypeptides are the ear- 
.O 
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liest polypeptides made and are the only 
ones made immediately following removal 
of inhibitors of protein synthesis, suggest- 
ing that they do not require prior protein 
synthesis in order for their mRNA to be 
expressed. The Q! polypeptides are encoded 
by the (Y mRNAs, or immediate early 
mRNAs, which represent 10 to 15% of the 
viral DNA. These immediate early mRNAs 
.are tw&&m&i~ tlieabuindcant &lass of viral 
transcripts early in infection, and map in 
nonconti~ous regions of the viral genome 
(Kozak and Roizman, 1974; Clements et al., 
1977; Jones et al., 1977). Following the ap- 
pearance of the cr polypeptides, new mRNA 
is required for the expression of the /3 poly- 
peptides (IIoness and Roizman, 1974; Pres- 
ton, 1979). However, all /3 polypeptide syn- 
thesis is not necessarily controlled by the 
same (Y polypeptide(s) (Pereira et al., 19’77; 
Preston, 19’79). The /3 mRNA species pre- 
sumably compose the remainder of the viral 
mRNA abundant prior to DNA synthesis. 
Taken together, the mRNA species en- 
coding cy and p proteins can be classified 
as early mRNA. Stringer et al. (1978) used 
R-loop mapping techniques to show this 
early mRNA maps in noncontiguous regions 
of the viral genome. Jones and Roizman 
(1979) used HSV-1 restriction fragments 
hybridized in solution to an excess of RNA 
to similarly show that the viral mRNA 
abundant in the presence of the DNA syn- 
thesis inhibitor phosphonoacetic acid is 
transcribed from noncontiguous regions 
throughout the viral genome. Using South- 
ern blot hybrid~ation of size-~actionated 
polyribosomal poly(A) RNA, we have been 
able to specifically identify and map 16 of 
these early abundant HSV-1 mRNA species 
(Holland et al., 1979). 
Although the early mRNA species are 
abundant prior to viral DNA synthesis, this 
is not in itself a sufficient condition to define 
the role of viral DNA replication in the 
normal expression of the late mRNA species 
coding for the synthesis of y proteins. It is 
possible that the presence of the /3 poly- 
peptides alone is su~cient for normal y 
polypeptide expression. Thus, y polypep- 
tides could be detected in cells where readily 
detectable viral DNA synthesis was inhib- 
ited, although their levels were reduced at 
least two- to threefold over normal levels 
(Honess and Roizman, 19’74; Powell et al., 
1975). However, Ward and Stevens (1975) 
examined total infected cell polypeptides 
from normal cells and from cells in which 
DNA synthesis was inhibited, and suggested 
a rigorous requirement for viral DNA repli- 
cation in expression of certain viral fune- 
tions. Honess and Watson (1977) have simi- 
lsr& shown ,tk& under stringent conditions 
for inhibition of HSV-1 DNA synthesis the 
late polypeptides are reduced by at least 
85%. Also, Powell et al. (1975) showed that 
certain late (y) viral polypeptides were 
missing in cells in the absence of DNA 
synthesis. 
Because of pleiotropic effects of DNA 
negative mut~ts (~arsden et al., 1976; 
Stow et al., 1978; Preston, 1979), the im- 
possibility of rigorously excluding some viral 
DNA synthesis under any experimental 
regime, and possible nonspecific toxic effects 
of inhibitory drugs, it is not clear that we 
can completely define the role of viral DNA 
replication in gene expression. We have, 
therefore, asked a more limited question: 
Does the inhibition of HSV-1 DNA synthe- 
sis result in a population of viral mRNA 
species of greater complexity than that seen 
prior to viral DNA replication? 
We have utilized our previously developed 
viral mRNA mapping procedures to ex- 
amine the viral mRNA abundant in the ab- 
sence of DNA synthesis. In order to inhibit 
viral DNA synthesis without inducing un- 
due toxic effects on the cells, we have used 
two nucleoside analogs of recent therapeutic 
interest, 9-P-D-arabinofuranosyladenine 
(ara-A) and l-/3-D-arabinofuranosylthymine 
(ara-T). The value of these drugs is based on 
the observation that, at therapeutic levels, 
they efficiently inhibit HSV-1 DNA synthe- 
sis while being relatively nontoxic to the 
host cells (Shipman et al., 1976; Aswell 
et al., 1977). 
In addition to mapping the viral mRNA 
species abundant when viral DNA replica- 
tion is inhibited, we have used HSV-1 DNA 
bound to cellulose as a reagent for the iso- 
lation of HSV-l-specific mRNA (Anderson 
et al., 1979; Holland et al., 1979). Such puri- 
fied viral mRNA is shown to be an efficient 
template for synthesis of viral polypeptides 
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in a reticulocyte lysate system. We find that 
viral polypeptides encoded by earlier mRNA 
in this system are the same as those seen 
using viral mRNA from the drug-treated 
cells and both are essentially a subset of 
those encoded by late viral mRNA. Taken 
together, these data confirm that viral DNA 
replication is necessary for the normal ex- 
pression of late viral genes. 
et al., 1977; Holland et al., 19’79). Poly- 
adenylated (poly(A)) RNA was purified 
by use of oligodeoxythymidylie acid-cellu- 
lose (oligo(dT)-cellulose, Collaborative Re- 
search, Inc.). 
MATERIALS AND METHODS 
Drugs. Ara-A was provided through the 
courtesy of Dr. Harold E. Machamer of 
Parke, Davis and Company, Detroit, Michi- 
gan. Pentostatin, a known adenosine de- 
aminase inhibitor (Woo et al., 1974), was 
also the gift of Dr. Machamer. This drug 
was used along with ara-A to insure that 
ara-A was not deaminated to the less ef- 
fective arabanosylhypoxanthine in the cells 
(Schwa~z et aE., 1976). Ara-T was kindly 
provided by Dr. G. A. Gentry, University 
of Mississippi Medical Center, Jackson, 
Mississippi. 
.Cells and vim~s. Monolayer cultures of 
HeLa cells were grown in Eagle’s minimum 
essential medium with Earle’s salts, 10% 
calf serum, and no antibiotics. Growth con- 
ditions and assay for mycoplasmal contami- 
nation were as previously described (Suther- 
land et al., 1975). Stocks of the KOS strain 
of HSV-1 were grown in HeLa cells at a 
multiplicity of infection of 0.1 PFUicell and 
prepared as previously described (Wager 
et al., 1976). 
Isolation of HSV-1 DNA. Supernatant 
and cytoplasmic virions purified from cells 
at 20 hr pi. by differential centrifugation 
were digested with proteinase Kin the pres- 
ence of 2% Sarkosyl and 0.5% sodium do- 
decyl sulfate (Holland et al., 1979). The viral 
DNA then was purified by a single cycle of 
isopycnic centrifugation (Wagneret al., 1974). 
Infection and labeling of cells. Infection 
at a multiplicity of 10 PFU/cell and labeling 
conditions for [32P]orthophosphate (New 
England Nuclear Corp.) and pH]uridine (28 
Cilmmol, ~hw~Mann) were as previously 
described (Holland et al., 1979). Cells were 
maintained on drug-containing or control 
medium for 1 hr before infection (or mock 
infection), and maintained continuously on 
drug-containing or control medium after in- 
fection (or mock infection) until extraction. 
Analysis of celldar and viral DNA syn- 
thesis. Cells grown in 25cm2 T-25 flasks 
(Corning Glass Works) were rinsed twice 
with cold 0.15 M NaCl, then lysed in the 
flask by the addition of 100 n&f NaCl- 10 n-&Z 
HEPES (N-2-hydroxyethylpiperazine-N’- 
2-ethanesulfonic acid)-20 m&f EDTA-2% 
Sarkosyl (pH 7.8). After digestion with 200 
pg proteinase Kim1 for at least 8 hr at 37”, 
samples were extracted with phenol and 
chloroform and ethanol precipitated. The 
nucleic acid pellet was dissolved in 0.1 
x SSC (SSC is 0.15 M NaCl-0.015 M Na, 
citrate), and its absorbance at 260 nm was 
determined. Two A,,, units (-100 pg> of 
each sample were adjusted to a final density 
of 1.700 g/ml by the addition of CsCl(6.551 g 
CsCl to 5 ml of sample). The gradients were 
layered with mineral oil, then spun for 44 hr 
at 44,000 rpm at 17” in a Beckman 65 rotor. 
Gradients were collected dropwise from the 
bottom into 0.175-ml fractions and refractive 
indexes were read to determine density. 
The TCA-insoluble material was collected 
on Whatman GF/C filters and the radioac- 
tivity was determined using toluene scintil- 
lation fluid. 
Viral RNA qu~nt~tat~o~ by solution hy- 
bridization. Samples for RNA quantitation 
were digested with 100 pg electrophoreti- 
tally purified DNase I (Sigma Chemical Co.) 
per milliliter in 10 n&f NaCl- 10 mM Tris- 
4.5 mM MgCl, (pH 7.4) for 20 min at 37”. 
Samples were adjusted to contain 100 n-&f 
NaCl-5 mM EDTA, then were phenol- 
chloroform extracted and ethanol precipi- 
tated. The RNA was stored in 100 d NaCl- 
10 nQ4 Tris-1 m&f EDTA (pH 7.4) at 20” .__ _ .-. 
~~01~~~0~ of RNA. Poly~bosome-associ- 
ated RNA was isolated from cells lysed with 
Triton X-100 by the Mg2+ precipitation 
method of Palmiter (1974), followed by pro- 
teinase K (Merck and Co., Inc.) digestion 
and,phenol-chlorofo~ extraction (Stringer until hybridization. 
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The proportion of HSV-1 specific RNA 
in RNA preparations was determined as by 
Rice et ~2. (1979). A small amount of radio- 
active RNA (0.2-1.5 pg), containing an un- 
known amount of viral RNA, was hybridized 
to an excess of HSV-1 DNA. Each hybridi- 
zation had a total DNA concentration (HSV-1 
or Escherichia coli) of 100 pg/ml, and the 
total RNA concentration was adjusted to 
1 mg/ml with uninfected HeLa cell RNA 
carrier. Hybridizations were carried out 
under mineral oil at 57” in 0.05 ml of 400 
mM Na+-100 m&f HEPES-5 mM EDTA 
(pH 8.0) (hybridization buffer) containing 
80% recrystallized formamide. These con- 
ditions allow HSV-1 DNA:RNA reassocia- 
tion in the absence of any DNA:DNA reas- 
sociation (Casey and Davidson, 1977; 
Holland et al., 1979). Hybridizations were 
carried out to a DNA C$ of 16-20, sufficient 
to drive the maximum amount of radioac- 
tivity into hybrid. Hybridized RNA was 
defined as the TCA-precipitable radioactiv- 
ity remaining after digestion with 50 pg 
pancreatic RNase (Sigma Chemical Co.) and 
10 units RNase T, (Calbiochem-Behring 
Corp.) per milliliter for 45 min at 37” in 2 
x SSC. The proportion of sample RNA that 
was viral was then calculated from the ef- 
ficiency of hybridization of a pure viral RNA 
sample included in each hybridization as a 
control (Rice et al., 1979). 
Hybridization to HSV-1 DNA-cellulose. 
Our modification of the Noyes and Stark 
(1975) procedure for the covalent coupling 
of DNA to cellulose has been published else- 
where (Anderson et al., 1979). In these ex- 
periments, lo-20 pg of poly(A) RNA was 
hybridized to 16-24 pg of HSV-1 DNA 
coupled to cellulose. Hybridizations were 
done in 0.1 ml of hybridization buffer con- 
taining 80% recrystallized formamide at 57 
for 4 hr. The eluted viral RNA was adjusted 
to 100 mM sodium acetate and ethanol pre- 
cipitated (Anderson et al., 1979). 
Restriction endonuclease digestion. The 
restriction endonucleases, BgZII, HindIII, 
and XbaI, were obtained from New England 
Biolabs. Digestion conditions were as 
described by the suppliers. Electropho- 
resis of restriction fragments was at room 
temperature on horizontal slabs (42 x 20 
X 1.2 cm) of 0.5% agarose (Sigma) contain- 
ing 0.5 pg ethidium bromide/ml for 48 hr 
at 70 mA (1.2 V/cm). The electrophoresis 
buffer (40 n-J4 Tris-5 mM sodium acetate- 
2 mM EDTA (pH 7.8)) was continuously 
circulated. 
The published restriction maps for HSV-1 
(Wilkie, 1976; Morse et al., 1977; Skare and 
Summers, 1977) have been confirmed for 
our virus strain (KOS) (Stringeret al., 1978; 
Anderson et al., 1979; Holland et al., 1979). 
One Hind111 restriction site is missing in 
our strain, resulting in the fusion of the two 
adjacent fragments (I and 0). To create 
minimum confusion in nomenclature, we 
have designated the fragment IO, leaving 
all other fragment designations consistent 
with those shown in a recent review by 
Roizman (1979). The four orientations of 
HSV-1 DNA and the resulting generation 
of half-molar and quarter-molar restriction 
fragments were clearly described by Roiz- 
man (1979) and will not be further discussed 
here. 
Blot hybridization of size-fractionated 
RNA. RNA samples were size-fractionated 
by electrophoresis on 1.2% agarose gels con- 
taining 10 mM methylmercury hydroxide 
(Alfa-Ventron) as described by Bailey and 
Davidson (1976). All procedures involving 
CH,HgOH were performed in a ventilated 
hood, and protective gloves were worn at 
all times. All contaminated materials were 
soaked in 50 mM p-mercaptoethanol prior 
to washing. Following electrophoresis, gels 
were soaked in 50 mM @mercaptoethanol 
for 20 min, then sliced in 3-mm intervals. 
Each RNA gel slice was dissolved in 1.5 
ml hybridization buffer containing 65% 
formamide by heating at 75” for 5 min. The 
method of Southern (1975) for transfer of 
DNA from agarose gels to nitrocellulose 
paper (BA85, Schleicher and Schuell Co.) 
was used to prepare DNA blots for hybridi- 
zation. Dissolved RNA gel samples and 
strips from the nitrocellulose DNA blots 
were sealed in plastic bags, hybridized at 
55” for 48 hr, rinsed, and autoradiographed 
as described (Holland et al., 1979). 
In vitro translation. RNA samples for 
translation were precipitated twice with 
ethanol. The final pellet was rinsed once 
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FIG. 1. Effect of ara-A and ara-T on HSV-1 DNA synthesis. CsCl equiIibrium density cent~~gation 
gradients from 32P-labeled infected cells, with and without drug treatment, are represented. Each 
gradient was fractionated into 0.175-ml fractions. The TCA-precipitable 32P counts for fractions of 
density 1.760 to 1.670 g/ml are shown (solid line). 3H-Labeled viral DNA was included in each gradient 
as a marker (dashed line). (A) Cells in drug-free medium labeled with 50 #Zi [S*P]orthophosphate/ml 
from 0 to 6 hr p.i. (B) Same as panel A, except labeled from 0 to 22 hr p.i. (C) Cells in medium 
containing 1.5 x IO-* M am-A and 3.7 x lo-” M pentostatin labeled with 50 &i ~P]o~hoph~phat~~ 
from 0 to 6 hr p.i. (Df Same as panel C, except labeled 0 to 22 hr p.i. (E) Cells in medium cont~~ng 
1.9 x lo-* M ara-T labeled with 50 MCi [3*P]orthophosphate/m1 from 0 to 6 hr p-i. (F) Same as panel E, 
except labeled 0 to 22 hr p.i. 
with cold 70% ethanol, dried under vacuum 
to remove all traces of ethanol, then dis- 
solved in a small volume of sterile, glass- 
distilled water. A micrococcal nuclease- 
treated rabbit reticulocyte lysate system 
(New England Nuclear) was used for in vitro 
translation of RNA samples. The optimum 
magnesium acetate concentration for trans- 
lation of HSV-1 mRNA was determined to 
be 0.5 n&. All other assay conditions were 
those recommended by the suppliers. Each 
25 ~1 assay contained 40-50 PCi [35S]me- 
thionine and 0.4-1.0 pg of RNA. Assays 
were incubated at 37” for 60 min and were 
terminated by adding 5 ~1 of 25 mM EDTA, 
containing 100 pg pancreatic RNase and 20 
units RNase T,/ml, and incubated an addi- 
tional 10 min at 37”. 
The polypeptide products from in vitro 
translation were fractionated by electropho- 
resis on discontinuous polyacrylamide slab 
gels containing 0.1% sodium dodecyl sulfate 
(Laemmfi, 1970). A 9% polyacry~amide sep- 
arating gel (10 cm x 14 cm x 1.5 mm) was 
used with a 3% polyacrylamide stacking gel. 
Dried gels were autoradiographed using 
Kodak NS-2T X-ray film. The molecular 
weights of labeled products were determined 
from their migration relative to both un- 
labeled molecular weight markers (Phar- 
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TABLE 1 
EFFECT OF ARABINOSYL NUCLEOSIDES ON HSV-1 DNA SYNTHESW 
cpm incorporated into DNA 
Cellular b Viral* 
O-6 hr pi. O-22 hr pi. O-6 hr p.i. O-22 hr p.i. 
Mock-infected 
No drug 457,800 2,070,700 - - 
Ara-A ND” ND - - 
Ara-T 170,800 714,600 - - 
Infected 
No drug 397,100 958,300 159,600 2,232,500 
Ara-A 37,600 283,900 11,200 30,300 
Ara-T 106,700 256,300 10,100 19,300 
4 Cells (2 x 106) were treated with either normal medium, medium containing 1.5 x 10e4 M ara-A and 3.7 
x lO+M pentostatin, or medium containing 1.9 x 10e4 M ara-T for 1 hr prior to the infection, or mock infection, 
of the cells with 10 PFU HSV-1 per cell. Infection, or mock infection, was for 30 min, followed by overlay with 5 ml 
of normal, or drug-containing, medium containing 50 &i [32P]orthophosphate/mI. 
* TCA-precipitable radioactivity incorporated during the labeling time shown. The radioactivity banding at a 
density of 1.685 to 1.710 g/ml was included as cellular DNA; radioactivity banding at a density of 1.715 to 1.735 
e/ml. which corresnonds to the nosition ofthe HSV-1 marker DNA in Fig. 1, was included as viral DNA. Each gra- 
dient contained 160 Fg (2 A,,,-units) of DNA. 
c Not done. 
macia) and the labeled products from in 
vitro translation of the adenovirus-1 infected 
HeLa cell RNA supplied with the transla- 
tion kit (Anderson et al., 1973; Lewis, et 
al., 1977). 
RESULTS 
Inhibition of HSV-1 DNA Synthesis by 
Ara-A and Ara-T 
In order to confirm previous reports on 
the effect of arabinosyl nucleosides on 
HSV-1 DNA synthesis (Drach and Shipman, 
1977; Aswell et al., 1977) for our cell and 
virus system, the following experiment was 
performed: Cultures of infected and mock- 
infected cells were grown in medium con- 
taining 50 FCi [32P]orthophosphate/m1, plus 
either 1.5 x 10e4 M ara-A and 3.7 x lo+ 
44 pentostatin, or 1.9 x 10e4 M ara-T, or 
no drug. The distribution of radioactivity 
from cells labeled for either 6 or 22 hr p.i. 
was then determined by CsCl equilibrium 
density centrifugation. Figure 1 shows not 
only the degree of separation of viral and 
cellular DNA obtainable by this method (A 
and B), but also the extent of inhibition of 
viral DNA synthesis due to the presence of 
ara-A/pentostatin (Figs. 1C and D) or ara-T 
(Figs. 1E and F). Gradient-purified 3H-la- 
beled HSV-1 DNA was included in each gra- 
dient as a marker. 
The results of the CsCl gradient analyses 
are summarized in Table 1. It was evident 
from the absence of significant radioactivity 
banding at the viral DNA density that the 
drug concentrations used reduced viral DNA 
synthesis by greater than 98%, compared 
with that seen in infected cells without drug 
exposure. This is a maximum estimate of 
the amount of viral DNA synthesis occur- 
ring in these cells, as the amount of back- 
ground radioactivity of viral density in 
uninfected cells was equivalent to the ra- 
dioactivity of viral density in the infected, 
drug-treated cells (not shown). Cellular 
DNA synthesis, however, was only reduced 
to about 30% of that observed for infected 
cells without drug exposure. These results 
are entirely consistent with previous re- 
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TABLE 2 
EFFECT OF ARABINOSYL NUCLEOSIDES ON HSV-1 RNA SYNTHESIS 
Percentage RNase-resistant radioactivity 
after DNA excess hybridization* 
Polyribosomal Poly(A+) Poly(A-) Percentage HSV-l-specific RNA 
RNA RNA RNA in sample’ 
Labeling period Experi- Experi- Experi- Polyribosomal Poly(A+) Poly(A-) 
of cells” mental HSV mental HSV mental HSV RNA RNA RNA 
l-2 hr pi. 
No drug 
5-6 hr p.i. 
No drug 
5-6 hr p.i. 
Ara-A 










O-6 hr p.i. (1) 4.8 
No drug (2) 6.5 
O-6 hr p.i. (1) ND 
Ara-A (2) ND 
O-6 hr p.i. (1) 1.7 
















93.9 0.9 95.3 
88.4 0.4 68.3 I 
3.9 
92.7 7.5 82.4 
84.4 8.5 88.8 I 38.6 
82.1 0.4 80.0 
86.8 0.3 92.6 I 
4.1 
77.7 0.6 85.7 
87.7 0.3 90.6 I 
4.1 
81.0 0.7 93.1 ND 
78.7 3.5 86.2 86.4 3.4 86.7 I 
6.8 
88.0 0.6 85.4 90.5 0.6 83.7 I 
ND 
81.7 0.5 88.5 










a Cells (1.2 x 10’) were treated for 1 hr prior to and during infection with either normal medium, medium 
containing 1.5 x 1O-4 M ara-A and 3.7 x 10Y6 M pentostatin, or medium containing 1.9 x 1O-4 M ara-T. Cells 
were pulse-labeled for 1 hr with 15 &i [3H]uridine/ml, or continuously labeled in the presence of 200 PCi 
[3ZP]orthophosphate/ml at the indicated times after infection. 
b Cytoplasmic RNA fractions were obtained as described under Materials and Methods. The hybridization 
mixtures contained 100 pg HSV-1 DNA/ml, 6000-8000 cpm of purified HSV-1 RNA as a standard, and either 
20,000-30,000 cpm (l), or 70,000-150,000 cpm (2) of the RNA sample to be tested. Total RNase-resistant 
radioactivity was adjusted by subtracting a background value determined by incubation of RNA with E. coli 
DNA. The adjusted percentage of input radioactivity resistant to RNase digestion is shown for both the test RNA 
sample (experimental column) and the viral RNA standard (HSV column). 
c Average of the values calculated from the ratio of the experimental to pure HSV samples. 
d Not determined. 
ports on the specificity of these drugs for 
inhibiting HSV-1 DNA synthesis (Drach 
and Shipman, 1977; Aswell et al., 1977). 
Therefore, the drug concentrations used in 
this examination of DNA synthesis were 
routinely used in our subsequent experi- 
ments in which the role of HSV-1 DNA 
replication in the expression of viral mRNA 
was examined. 
Quantitation of HSV-1 mRNA Associated 
with Polyribosomes 
The cytoplasmic RNA population of HSV-1 
infected cells was examined by using two 
different labeling protocols. To examine the 
amount of viral-specific newly synthesized 
RNA, infected cells with and without drug 
treatment were pulse-labeled with. 15 &i 
CONTROL OF HSV-1 mRNA EXPRESSION 17 
t3H]u~dine/ml for 1 hr prior to extraction. 
To examine the total amount of viral-specific 
RNA present, infected cells with and with- 
out drug treatment were continuously la- 
beled from the time of infection to extraction 
with 200 &i [32P]orthophosphate/ml. Total 
polyribosomal-associated RNA, poly(A+) 
polyribosomal RNA, and poly(A-) poly- 
ribosomal RNA were hybridized in solution 
to an excess of HSV-1 DNA. The results 
of these quantitative hyb~d~ations, ex- 
pressed as the propo~ion of RNase-resist~t 
radioactivity found after hybridization, are 
shown in Table 2. Raw data were corrected 
by subtracting a background RNase-resist- 
ant radioactivity determined in a parallel 
experiment using E. co2i DNA instead of 
HSV-1 DNA. Both 32P-labeled and 3H-la- 
beled HSV-1 specific RNA, prepared by 
preparative hybridization to HSV-1 DNA 
coupled to cellulose, were included, respec- 
tively, in the quantitative hyb~d~ations of 
the 3H pulse-labeled samples and the 32P 
continuously labeled samples to standardize 
the efficiency of hybridization. The amount 
of the control viral RNA hybridized ranged 
from 69 to 95% (Table Z), and the data were 
normalized relative to 100% hybridization 
for the HSV-1 RNA. All samples used in 
quantitative hybridizations were thoroughly 
DNase digested prior to hybrid~ation to 
remove any trace amounts of contaminating 
labeled DNA. 
The results shown in Table 2 support our 
earlier finding that, at late times after in- 
fection when viral DNA synthesis is maxi- 
mal, the vast majority of the labeled mRNA 
is virus specific (Stringer et al., 1977). How- 
ever, at late times of infection in the pres- 
ence of drugs inhibitory for HSV-1 DNA 
synthesis, the proportion of the mRNA hav- 
ing viral origin was greatly reduced com- 
pared to that seen with the same labeling 
time in the absence of drugs. The amount 
of viral mRNA at late times of infection 
in the presence of ara-A or ara-T thus ap- 
peared to be very similar to that seen at 
very early times in the infection (prior to 
the start of viral DNA replication). These 
correlations held true for each of the RNA 
populations examined, as well as with both 
labeling protocols. 
Effect of Ara-A and Ara-T on the Appear- 
ance of ~p~~~~ Vicar mRNA Species 
We previously have shown that hybridi- 
zation of size-fractionated RNA to Southern 
blots of restriction enzyme-digested HSV-1 
DNA enables us to identify specific viral 
mRNA species (Anderson et al., 1979; Hol- 
land et al., 1979). The viral mRNA species 
obtained from drug-treated cells were also 
examined by Southern blot hybrid~ation. 
The infected cells were labeled with 500 FCi 
of [32P]orthophosphate/ml immediately fol- 
lowing the adsorption period. The 32P-labeled 
polyribosome-associated RNA was ex- 
tracted at either 2 hr p.i. (early no-drug 
control) or 6 hr p.i. (drug-treated and late 
no-drug control). The polyadenylated RNA 
was isolated on oligo(dT)-cellulose, prepara- 
tively hybridized in solution to HSV-1 DNA 
covalently coupled to cellulose, and size- 
fractionated on denatu~ng methylmercury 
agarose gels. Discrete size fractions of this 
purified viral mRNA then were hybridized 
to HindIIIIXbaI double-digest blots of 
HSV-1 DNA. The location of the restriction 
fragments on the HSV-1 genome is shown 
in Fig. 2. 
The results of the Southern blot hybridi- 
zations are shown in Fig. 3. The early (Fig. 
3A) and late (Fig. 3D) no-drug controls 
showed the same patterns of hybridization 
as in our previous reports (Anderson et al., 
1979; Holland et al., 1979). The use of pre- 
paratively hybridized viral RNA in these 
experiments, as opposed to total poly(A) 
RNA in our previous reports, caused no 
qualitative difference in the viral RNA 
species observed. However, some quantita- 
tive differences were detected, These were 
caused by an enhancement of less abundant 
species by the preparative hyb~d~ation. 
By comparing the viral mRNA species 
expressed “late,” either in the presence of 
ara-A plus pentostatin (Fig. 3B) or in the 
presence of ara-T (Fig. 30, with those 
seen in the two control experiments, it can 
be seen that the viral species present in 
drug-treated cells resembled very closely 
those species occurring in the early control 
and appeared to be a subset of the species 
observed in the late control. Several dis- 
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FIG. 2. Map of restriction endonuclease fragments of the KOS strain of HSV-1. The fragments 
generated from cleavage by restriction endonuclease Bg111, HindIII, X&I, Hind111 plus XbaI, and 
HpaI digests are shown for the prototypical arrangement of our HSV-1 strain, The origin of these 
restriction maps and confirmation of our strain (KOS) have been described previously (Stringer et al., 
1978; Anderson et al., 1979; Holland et ccl., 1979). The structure and rearrangements of HSV-1 DNA 
have been reviewed recently (Roizman, 1979). Additional discussion of these restriction maps is by 
Holland et al. (1979). 
tinguishing features are readily identifiable. 
For example, the 7-kb RNA hybridizing to 
Hind111 fragment K is only detectable in 
the presence of DNA synthesis (Fig. 3D, 
compare with A, B, C). The 1.7-kb RNA 
hybridizing to HindIIIIXBAI double-digest 
fragment AE and the 1.5kb RNA hybridiz- 
ing to Hind111 fragment G are similarly 
absent without viral DNA replication. The 
6-kb RNA hyb~d~ing to Hind111 fragment 
J, although present in small amounts in the 
early (Fig. 3A) and drug-treated samples 
(Figs. 3B, C), is much more abundant rela- 
tive to other species in the late control cells 
(Fig. 3D). Viral DNA synthesis is required 
for this mRNA species to become a major 
abundant species. The RNA of 2.8 kb hy- 
bridizing to XbaI fragment G appeared as 
a more prominent species in the early eon- 
trol (Fig. 3A) than it did in the drug-treated 
(Figs. 3B, C) or late control (Fig. 3D) 
samples. The intensity of the spot decreased 
with longer labeling times. This is in con- 
trast to the 3-kb RNA hybridizing to H&d111 
fragment G, which increased with the longer 
labeling times, 
Other distinguishing features are evident 
in the hybridization of 3.3- and 2.8-kb RNA 
species shown in Fig. 4, Hyb~d~ation of 
3.3kb RNA to blots of~g~II-diges~d HSV-1 
DNA showed hyb~d~ation only to BglII 
fragment I for the early control (Fig. 4B), 
ara-A-treated (Fig. 4C), and ara-T-treated 
(Fig. 4D) cells. This correlated with the 
3.3-kb RNA seen hybridizing to the XbaI 
fragment F (see Figs. 2 and 3). However, 
3.3-kb RNA from the late control cells 
showed additional hybridization to the BgZII 
fragments M and N (Fig. 4E). The 2%kb 
RNA from the late control cells, which hy- 
bridized to the baud cont~ing both H&dIIU 
XbaI double-digest fragment LE and Hind- 
III fragment M (Fig. 3D), is shown in Fig. 
4H to hybridize to the Hind111 fragment 
L and not Hind111 fragment M. The RNA 
that is 2.8 kb in size from the ara-T-treated 
cells does not contain this mRNA species 
(Fig. 4G). 
We compared the translation products of 
purified HSV-1 mRNA from infected cells 
isolated at early, late, and late times in the 
presence of ara-Alpentostatin or ara-T with 
that of total poly(A) RNA from these and 
mock-infected cells. Our procedures for the 
isolation and purification of viral mRNA via 
use of DNA cellulose were as described 
above and under Materials and Methods. 
Samples of RNA (0.4-1.0 pg) were trans- 
lated individually and the polypeptides frae- 
tionated by SDS-gel electrophoresis (Fig. 
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FIG. 3. Southern blot analysis of size-fractionated viral RNA from control and drug-treated cells. 
Polyadenylated polyribosomal RNA was preparatively hybridized to HSV-1 DNA coupled to cellu- 
lose (see Materials and Methods). The eluted viral mRNA was then size-fractionated by electrophoresis 
in agarose gels containing 10 mM methylmercury hydroxide as previously described (Anderson et al., 
1979; Holland et al., 1979). The 3-mm gel slices were dissolved and hybridized to individual strips of 
HindIIIIXbaI double-digest blots of HSV-1 DNA for 48 hr at 47” (see Materials and Methods). The 
top two-thirds of these blots is shown. The RNA size in kilobaaes is shown across the top of each 
panel and was determined from the position of 28 S (5.2 kb) and 13 S (2 kb) HeLa cell rRNA run in 
parallel gels. After hybridization, the strips were rinsed and reassembled according to RNA size. 
Autoradiography was for 24 hr at -70” using two intensifying screens. (A) HSV-l-specific mRNA 
from cells labeled from 0 to 2 hr p.i. with 500 &i [32P]orthophosphate/ml in the absence of drugs. 
(B) Viral mRNA from cells labeled from 0 to 6 hr p.i. with 500 &i [32P]orthophosphate/ml in the 
presence of 1.5 x 10e4 M ara-A and 3.7 x W6 M pentostatin. (C) Viral mRNA from cells labeled 
from 0 to 6 hr p.i. with 500 &i [32P]orthophosphate/ml in the presence of 1.9 x 10m4 M ara-T. (D) Viral 
mRNA from cells labeled from 0 to 6 hr p.i. with 500 &i [32P]orthophosphate/ml in the absence of 
drugs. (G) The guide strip showing the position and resolution of the fragments was made from a similar 
blot-using 32P-labeled total late pily(A) RNA. 
5A). A second experiment was carried out 
using only early or late HSV-1 mRNA and 
the polypeptides were run in a separate gel 
to clearly delineate the viral polypeptides 
seen at these times after infection (Fig. 5B). 
In contrast to the large number of poly- 
peptides in the size range of 170,000 to 41,000 
d encoded by uninfected HeLa cell mRNA 
(Fig. 5A, track 2), early viral mRNA coded 
for a limited number of discrete polypeptide 
bands (Fig. 5A, track 4; Fig. 5B). The ma- 
jority of these polypeptides have no counter- 
part in the translation products of RNA 
from mock-infected cells, demonstrating the 
high specificity of our method for the pre- 
parative isolation of HSV-1 mRNA. Most 
of the viral polypeptides seen using early 
viral mRNA as a template are also seen 
when late (6 hr p.i.) viral mRNA is used 
(Fig. 5A, track 9; Fig. 5B). One notable 
exception is the 170,000-d polypeptide, 
which is absent using late HSV-1 mRNA 
or late poly(A+) mRNA as a translation 
template. In addition to these polypeptides, 
a large number of new viral polypeptides 
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FIG. 4. Rehybridization of 3.3- and 2.8-kb RNA species to other restriction fragment blots. The RNA 
of these sizes from selected samples of Fig. 3 were rehybridized to either BgEII or Hind111 blots 
of HSV-1 DNA. (A) Guide strip showing position and band separation for BglII digests. (B) The 3.3-kb 
RNA from early control cells labeled 0 to 2 hr p.i. (Fig. 3A) hybridized to such a blot. (C) The 3.3-kb 
RNA from ara-A/pentostatin-treated cells labeled 0 to 6 hr p.i. (Fig. 3B) hybridized to another BglII 
blot. (D) The 3.3-kb RNA from ara-T-treated cells labeled 0 to 6 hr p.i. (Fig. 3C) hybridized to aBglI1 
blot. (E) The 3.3-kb RNA from late control cells labeled 0 to 6 hr p.i. (Fig. SD) hybridized to a BglII 
blot. (F) A guide strip showing position and band separation for H&d111 digests. (G) The 2.8-kb RNA 
from ara-T-treated cells labeled 0 to 6 hr p-i. (Fig. 3C) hybridized to a Hind111 blot. (H) The 2.8-kb 
RNA from late control ceils labeled 0 to 6 hr p.i. (Fig. 3D) hybridized to a Hind111 blot. 
mRNA compared to early. The changes in 
viral polypeptides seen are entirely consis- 
tent with results of our mRNA mapping 
studies. We have indicated the major 
changes seen in Fig. 5B. 
Th effect of inhibition of viral DNA syn- 
thesis using ara-A/pentostatin or ara-T on 
the template activity of viral mRNA is ap- 
parent from the data of Fig. 5A. The poly- 
peptides made using total poly(A) RNA 
from early control (track 3), ara-A-treated 
(track 6), and ara-T-treated (track 7) in- 
fected cells showed a complex pattern that 
appeared similar to the pattern seen using 
poly(A) RNA from uninfected cells (track 2), 
with the addition of new bands of 170,000, 
140,000,125,000,120,000, and 64,000 d easily 
identifiable. This result was consistent with 
our quantitation experiments (see Table 2), 
which showed large amounts of cellular 
poly(A) RNA remaining associated with 
polyribosomes under these conditions of in- 
fection. ~anslation of viral mRNA from 
these drug-treated eells, as well as in cells 
m~ntained in ara-T medium for 18 hr (not 
shown), resulted in the synthesis of the 
same polypeptides seen using early viral 
mRNA as a template (compare tracks 4, 5, 
and 8 of Fig. 5A). 
A dramatic change in the proportion of 
viral mRNA on polyribosomes was observed 
by translation of total polyribosomal poly(A) 
RNA obtained from late control cells (Fig. 
5A, track 11). In this case, virtually the 
same polypeptides were seen as when viral- 
specific mRNA was used as a template (track 
9). Only one cell-specific polypeptide (of 
about 48,000 d), translated from the total 
late poly(A) RNA, was resolvable from the 
virus-specific polypeptides. These results 
also were consistent with our quantitation 
data, which showed the majority of the poly- 
ribosomal poly(A) RNA late after infection 
to be viral (Table 2). 
DISCUSSION 
The experiments presented here, which 
describe viral mRNA from cells early (2 hr 
pi., prior to the onset of viral DNA synthe- 
sis) or late in infection (6 hr p.i., during 
maximal viral DNA synthesis), or under 
conditions where viral DNA synthesis has 
been blocked (6 hr p.i., cells treated with 
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FIG. 5. Products from in vitro translation of viral and total polyribosome-associated polyadenylated 
RNA. A commercial rabbit reticulocyte lysate system was used for in vitro translation of both total 
polyribosomal polyadenylated RNA (A+ samples) and polyribosome-associated viral poly(A) RNA 
purified by preparative hybridization to HSV-1 DNA bound to cellulose (HSV-1 samples). Following 
translation, polypeptides were denatured and subjected to SDS-acrylamide gel eleetrophoresis as 
described under Materials and Methods. A sample of adenovirus infected cell mRNA (supplied with 
the kit) was translated and the polypeptides were run as internal size markers. The molecular weights 
of these standards were con6rmed by their migration relative to commercial, nonradioactive size 
standards electrophoresed in adjacent slots and visualized by staining with Coomassie brilliant blue. 
(A) Samples of poly(A) or HSV-l-specific mRNA from drug-treated and control cells. Sizes of selected 
adenovirus polypeptides are shown on the left. The tracks are translation products of (from the left): 
(1) adenovirus RNA; (2) mock-infected HeLa polyribosomal poly(A+) RNA; (3) polyribosomal 
poly(At) RNA from cells 2 hr p.i.; (4) HSV-l-specific mRNA from these cells; (6) ~l~bosomal 
polyfA+) RNA from sueh cells; (‘7) ~ly~bosomal poly(A+) RNA from ara-T-treated fells; (8) HSV-I- 
specific mRNA from ara-T-treated cells; (9) HSV-l-specific mRNA from cells 6 hr p.i.; (10) adenovirus 
RNA; (11) polyribosomal poly (A+) RNA from cells 6 hr p.i.; (12) no RNA. (B) Separate samples 
of early (2 hr p.i.) and late (6 hr pi.) HSV-l-specific mRNA were translated and fractionated. 
The polypeptide bands seen using late HSV-1 mRNA, and not present using early, are indicated 
along with their sizes on the right. The 170,096-d protein not seen late is indicated by the dashed line. 
ara-A or araT), have been directed toward 
elucidating the role of HSV-1 DNA replica- 
tion in gene expression. The amounts of 
viral mRNA or polyribosomes obtained 
from infected cells growing either in the 
absence or presence of viral DNA synthesis, 
the distinct viral mRNA species identifiable 
in these mRNA populations, and the viral 
mRNA-specified polypeptides synthesized 
in vitro, are all consistent with a model re- 
quiring HSV-1 DNA synthesis for efficient 
late viral gene expression. By all these cri- 
teria, inhibition of viral DNA synthesis, 
over long enough time periods to allow ef- 
ficient expression of late mRNA in control 
cells, results in a viral mRNA population 
typical of cells early after infection. 
In addition to this conclusion, the com- 
parison of individual mRNA species and 
their in vitro translation products confirms 
that several levels of viral mRNA abundance 
exist in HSV-1 infected cells. Viral mRNA 
species can be divided into groups on the 
basis of their relative abundance at various 
times after infection (see Fig. 3). Several 
of the mRNA species which appear as abun- 
dant species prior to viral DNA replieation 
continue to be expressed as major species 
during viral DNA synthesis (i.e., the 5.3-kb 
mRNA in Hind111 fragment K; the 4.3-, 
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3.3-, and 1.5kb mRNAs in XbaI fragment 
F >. Their abundance is maintained or fur- 
ther increased upon viral DNA replication. 
We classify these as early mRNA species. 
Members of a second group are charac- 
terized by a dependence on viral DNA syn- 
thesis for appearance as major mRNA 
species. Some of these cannot be detected 
at all prior to viral DNA synthesis (i.e., 
the 7-kb mRNA in Hind111 fragment K; 
the 2%kb mRNA in Hind111 fragment L; 
and a number of species mapping elsewhere 
.in$he final-gen~me,su~hasin~~~dIII frag- 
ment J). Others are detectable, but at re- 
duced levels in the absence of viral DNA 
synthesis (i.e., the 6-kb mRNA mapping in 
IiindIII fragment J). We cannot, at this 
time, determine whether the differences ob- 
served for these species are due to differ- 
ences in steady state levels early, or to actual 
differences in levels of transcription at these 
times. However, it is clear that only with 
HSV-1 DNA replication are any of these 
viral mRNA species seen in their normal 
amounts. The continued expression of some 
of these mRNAs is probably responsible for 
the presence of small amounts of certain y 
polypeptides in viva in cells incubated for 
long times in the absence of DNA replication 
(Powell et al., 1975). This group, as a whole, 
is classified as late mRNA. 
In addition to these two temporal group- 
ings of viral mRNA, there are several other 
patterns seen. At least one mRNA species 
(the 2.8-kb mRNA in HindIII fragment G) 
increases in abundance with labeling time, 
even in the absence of viral DNA synthesis. 
This could be an early viral mRNA with a 
very long half-life, thus causing its accumu- 
lation. Finally, there is a group of viral 
mRNA species which decrease in relative 
abundance with time of infection (4 kb in 
Il;lindIII fragment G; 2.8 kb in XbaI frag- 
ment G). The decline of the 4-kb species 
accounts for the decreased synthesis, or ab- 
sence, of the 170,~OO d early viral polypep- 
tide at late times (Watson et al., 1979; An- 
derson, Holland, Costa, and Wagner, in 
preparation). Further experiments will be 
required to establish what factors in viral 
gene expression are responsible for these 
atypical patterns. 
In vitro translation of viral mRNA iso- 
lated under our experimental conditions 
clearly confi~s that the inhibition of HSV-1 
DNA synthesis results in the expression of 
the same restricted viral mRNA population 
seen early. Further, these early viral poly- 
peptides are a subset of the viral polypep- 
tides encoded late during normal viral DNA 
replication. Our results are, to our knowl- 
edge, the first report of in vitro translation 
of purified HSV-1 mRNA. Correlation of 
the viral polypeptides identified by in vitro 
translation here with those identified from 
total infected cell mRNA by others (Cremer 
et al., 1977,1978; Preston, 1977, 1979; Wat- 
son et ai., 1979) is quite good. However, 
several additional viral polypeptides are 
evident with purified viral mRNA due to 
our specific elimination of cellular back- 
ground. We currently are carrying out stud- 
ies on the isolation and translation of in- 
dividual mRNA species which will result in 
the precise localization of viral mRNA 
species seen at all stages of replication. 
It is important to emphasize that the re- 
sults presented here reflect only the viral 
mRNA species of major abundance occur- 
ring at the times examined. Our data sug- 
gest that the sequences of low abundance 
early depend upon viral DNA synthesis for 
sufficient amplification to permit translation 
at levels comparable to those existing for 
the abundant species found early. Whether 
this amplification is required to provide suf- 
ficient biological activity, or is merely a con- 
sequence of viral DNA replication, is not 
clear. One possible mechanism for control 
of this amplification is suggested by the 
finding of cellular proteins specificaIly as- 
sociated with infecting viral DNA, but not 
with newly synthesized viral DNA (Rice et 
al., 1976). Further characterization of the 
viral mRNA species and specific correlation 
of the mRNAs with polypeptides and func- 
tions will elucidate the significance of these 
observations. 
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